You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

~ Buy the BELSOMRA (suvorexant) Drug Profile, 2024 PDF Report in the Report Store ~

belsomra Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Belsomra, and when can generic versions of Belsomra launch?

Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in thirty-six countries.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this compound. Additional details are available on the suvorexant profile page.

DrugPatentWatch® Generic Entry Outlook for Belsomra

Belsomra was eligible for patent challenges on August 13, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 20, 2029. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for belsomra?
  • What are the global sales for belsomra?
  • What is Average Wholesale Price for belsomra?
Summary for belsomra
International Patents:75
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 60
Clinical Trials: 33
Patent Applications: 198
Drug Prices: Drug price information for belsomra
What excipients (inactive ingredients) are in belsomra?belsomra excipients list
DailyMed Link:belsomra at DailyMed
Drug patent expirations by year for belsomra
Drug Prices for belsomra

See drug prices for belsomra

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for belsomra
Generic Entry Date for belsomra*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for belsomra

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Maryland, BaltimorePhase 2
Merck Sharp & Dohme LLCPhase 2
Columbia UniversityPhase 4

See all belsomra clinical trials

Paragraph IV (Patent) Challenges for BELSOMRA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BELSOMRA Tablets suvorexant 5 mg, 10 mg, 15 mg and 20 mg 204569 1 2024-03-04

US Patents and Regulatory Information for belsomra

belsomra is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of belsomra is ⤷  Subscribe.

This potential generic entry date is based on patent ⤷  Subscribe.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-001 Aug 13, 2014 RX Yes No ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-003 Aug 13, 2014 RX Yes No ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-002 Aug 13, 2014 RX Yes No ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-004 Aug 13, 2014 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-003 Aug 13, 2014 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-001 Aug 13, 2014 RX Yes No ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for belsomra

When does loss-of-exclusivity occur for belsomra?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 3979
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAM SUSTITUIDOS
Estimated Expiration: ⤷  Subscribe

Patent: 8881
Patent: UNA COMPOSICION FARMACEUTICA QUE COMPRENDE 5-CLORO-2-{(5R)-5-METIL-4-[5-METIL-2-(2H-1,2,3-TRIAZOL-2-IL)BENZOIL]-1,4-DIAZEPAN-1-IL}-1,3-BENZOXAZOL; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y SU USO EN LA PREPARACION DE MEDICAMENTOS
Estimated Expiration: ⤷  Subscribe

Australia

Patent: 07328267
Patent: Substituted diazepan compounds as orexin receptor antagonists
Estimated Expiration: ⤷  Subscribe

Patent: 10249269
Patent: Substituted diazepan compounds as orexin receptor antagonists
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 0719361
Patent: COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA, USO DE UM COMPOSTO OU DE UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO, MÉTODOS PARA MELHORAR A QUALIDADE DO SONO EM UM PACIENTE MAMÍFERO, PARA TRATAR INSÔNIA EM UM PACIENTE MAMÍFERO E PARA TRATAR OU CONTROLAR OBESIDADE EM UM PACIENTE MAMÍFERO
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 70892
Patent: ANTAGONISTES DES RECEPTEURS DE L'OREXINE SOUS FORME DE COMPOSES DE DIAZEPANE SUBSTITUES (SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 07003441
Patent: COMPUESTOS DERIVADOS DE 1,4-DIAZEPAM SUSTITUIDO, ANTAGONISTAS DEL RECEPTOR DE OREXINA; COMPOSICION FARMACEUTICA; Y USO PARA EL TRATAMIENTO O PREVENCION DE UN TRASTORNO DEL SUENO, PARA POTENCIAR LA CALIDAD DEL SUENO, Y PARA TRATAR O CONTROLAR LA OBESI
Estimated Expiration: ⤷  Subscribe

Patent: 10001173
Patent: Compuestos derivados de 1,4-diazepam sustituido, antagonistas de ox1 y ox2; utiles para preparar un medicamento destinado al tratamiento o prevencion de un trastorno del sueño,para potenciar la calidad del sueno,y para tratar o controlar la obesidad.(divisional de la sol.n 3441-07)
Estimated Expiration: ⤷  Subscribe

China

Patent: 1627028
Patent: Substituted diazepan compounds as orexin receptor antagonists
Estimated Expiration: ⤷  Subscribe

Patent: 1880276
Patent: Substituted diazepan compounds as orexin receptor antagonists
Estimated Expiration: ⤷  Subscribe

Colombia

Patent: 90524
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAM SUSTITUIDO
Estimated Expiration: ⤷  Subscribe

Costa Rica

Patent: 859
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAM SUSTITUIDO
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0130002
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 13798
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 89382
Estimated Expiration: ⤷  Subscribe

Dominican Republic

Patent: 009000126
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAN SUSTITUÍDO
Estimated Expiration: ⤷  Subscribe

Ecuador

Patent: 099374
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAN SUSTITUIDO
Estimated Expiration: ⤷  Subscribe

El Salvador

Patent: 09003276
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAN SUSTITUIDO
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 89382
Patent: ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE SOUS FORME DE COMPOSÉS DE DIAZÉPANE SUBSTITUÉS (SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS)
Estimated Expiration: ⤷  Subscribe

Patent: 92572
Patent: Antagonistes des récepteurs de l'orexine sous forme de composés de diazépane substitués (Substituted diazepan compounds as orexin receptor antagonists)
Estimated Expiration: ⤷  Subscribe

Honduras

Patent: 09001067
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAN SUSTITUIDO
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 28691
Patent: SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 75427
Estimated Expiration: ⤷  Subscribe

Patent: 35758
Estimated Expiration: ⤷  Subscribe

Patent: 67803
Estimated Expiration: ⤷  Subscribe

Patent: 10511621
Estimated Expiration: ⤷  Subscribe

Patent: 11068665
Patent: SUBSTITUTED DIAZEPAN COMPOUND AS OREXIN RECEPTOR ANTAGONIST
Estimated Expiration: ⤷  Subscribe

Patent: 11079848
Patent: SUBSTITUTED DIAZEPANE COMPOUND AS OREXIN RECEPTOR ANTAGONIST
Estimated Expiration: ⤷  Subscribe

Malaysia

Patent: 1834
Patent: SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 09005712
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAM SUSTITUIDO. (SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS.)
Estimated Expiration: ⤷  Subscribe

Morocco

Patent: 016
Patent: COMPOSES DE DIAZEPAN SUBSTITUES COMME ANTAGONISTES DES RECEPTEURS DE L'OREXINE.
Estimated Expiration: ⤷  Subscribe

New Zealand

Patent: 7334
Patent: SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
Estimated Expiration: ⤷  Subscribe

Nicaragua

Patent: 0900100
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAN SUSTITUIDO
Estimated Expiration: ⤷  Subscribe

Norway

Patent: 2586
Estimated Expiration: ⤷  Subscribe

Patent: 092470
Estimated Expiration: ⤷  Subscribe

Peru

Patent: 081229
Patent: ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAM SUSTITUIDO
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 89382
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 89382
Estimated Expiration: ⤷  Subscribe

Russian Federation

Patent: 58924
Patent: СОЕДИНЕНИЯ ЗАМЕЩЕННЫХ ДИАЗЕПАНОВ В КАЧЕСТВЕ АНТАГОНИСТОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ (DIAZEPANE SUBSTITUTED COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS)
Estimated Expiration: ⤷  Subscribe

Patent: 61727
Patent: СОЕДИНЕНИЯ ЗАМЕЩЕННЫХ ДИАЗЕПАНОВ В КАЧЕСТВЕ АНТАГОНИСТОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ (COMPOUNDS OF SUBSTITUTED DIAZEPANES AS ANTAGONISTS OF OREXIN RECEPTORS)
Estimated Expiration: ⤷  Subscribe

Patent: 09125024
Patent: СОЕДИНЕНИЯ ЗАМЕЩЕННЫХ ДИАЗЕПАНОВ В КАЧЕСТВЕ АНТАГОНИСТОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
Estimated Expiration: ⤷  Subscribe

Patent: 10150818
Patent: СОЕДИНЕНИЯ ЗАМЕЩЕННЫХ ДИАЗЕПАНОВ В КАЧЕСТВЕ АНТАГОНИСТОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
Estimated Expiration: ⤷  Subscribe

Serbia

Patent: 617
Patent: SUPSTITUISANA JEDINJENJA DIAZEPANA KAO ANTAGONISTI RECEPTORA ZA OREKSIN (SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS)
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 89382
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 0903334
Patent: Substituted diazepan compounds as orexin receptor antagonists
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 1217057
Estimated Expiration: ⤷  Subscribe

Patent: 1299426
Estimated Expiration: ⤷  Subscribe

Patent: 090087110
Patent: SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
Estimated Expiration: ⤷  Subscribe

Patent: 100031767
Patent: SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 97188
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 13696
Estimated Expiration: ⤷  Subscribe

Patent: 15188
Estimated Expiration: ⤷  Subscribe

Patent: 0831494
Patent: Substituted diazepan orexin receptor antagonists
Estimated Expiration: ⤷  Subscribe

Patent: 1109318
Patent: Substituted diazepan orexin receptor antagonists
Estimated Expiration: ⤷  Subscribe

Ukraine

Patent: 0974
Patent: СОЕДИНЕНИЯ ЗАМЕЩЕННЫХ ДИАЗЕПАНОВ КАК АНТАГОНИСТЫ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ;СПОЛУКИ ЗАМІЩЕНИХ ДІАЗЕПАНІВ ЯК АНТАГОНІСТИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ (SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS)
Estimated Expiration: ⤷  Subscribe

Patent: 6873
Patent: СПОЛУКИ ЗАМІЩЕНИХ ДІАЗЕПАНІВ ЯК АНТАГОНІСТИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering belsomra around the world.

Country Patent Number Title Estimated Expiration
China 109078015 食欲素受体拮抗剂的固体剂量制剂 (Solid dosage formulations of an orexin receptor antagonist) ⤷  Subscribe
Nicaragua 200900100 ANTAGONISTAS DE RECEPTOR DE OREXINA DE DIAZEPAN SUSTITUIDO ⤷  Subscribe
Mexico 2014014644 FORMULACIONES DE DOSIS SOLIDA DE UN ANTAGONISTA DEL RECEPTOR DE OREXINA. (SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST.) ⤷  Subscribe
Russian Federation 2014152031 СОСТАВЫ ТВЕРДЫХ ДОЗИРОВАННЫХ ЛЕКАРСТВЕННЫХ ФОРМ АНТАГОНИСТА ОРЕКСИНОВОГО РЕЦЕПТОРА ⤷  Subscribe
Canada 2795550 FORMES PHARMACEUTIQUES POSOLOGIQUES SOLIDES D'UN ANTAGONISTE DES RECEPTEURS DES OREXINES (SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST) ⤷  Subscribe
Brazil 112014025041 composição farmacêutica ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Belsomra Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for BELSOMRA

Introduction

BELSOMRA (suvorexant), developed by Merck, is a groundbreaking insomnia treatment that has been making significant waves in the pharmaceutical industry since its approval in 2015. This article delves into the market dynamics and financial trajectory of BELSOMRA, highlighting its impact, growth prospects, and the challenges it faces.

Mechanism of Action and Market Position

BELSOMRA is the first and only orexin receptor antagonist approved for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. By selectively blocking orexin receptors, it suppresses the wake drive in the brain, offering a new mechanism of action distinct from traditional hypnotics like benzodiazepines and Z-drugs[3].

Market Outlook and Growth Prospects

The insomnia treatment market, where BELSOMRA operates, is anticipated to grow at a compound annual growth rate (CAGR) of 2.6% from $3.2 billion in 2022 to $4.1 billion in 2032 across the seven major markets. This growth is largely driven by the increasing patient share of dual orexin receptor antagonists (DORAs), a category that includes BELSOMRA, Eisai’s Dayvigo (lemborexant), and Idorsia’s Quviviq (daridorexant)[1].

Sales Performance

Since its launch, BELSOMRA has shown promising sales performance. By February 2015, it had already surpassed 1,000 weekly prescriptions in the US, and its potential market was estimated at around 2 billion doses per year when including Japan[4].

Financial Impact on Merck

The financial performance of BELSOMRA is closely tied to Merck's overall pharmaceutical sales. In the third quarter of 2024, Merck reported total worldwide sales of $16.7 billion, with pharmaceutical sales increasing by 5% driven by growth in various therapeutic areas, although the specific contribution of BELSOMRA was not detailed in this report[2].

Revenue Contribution

While the exact revenue generated by BELSOMRA is not separately disclosed in Merck's recent financial reports, it is part of the broader insomnia treatment market that is expected to contribute significantly to Merck's revenue. The launch of BELSOMRA and other DORAs has been instrumental in capturing patient share from traditional hypnotics, thereby driving revenue growth[1].

Market Challenges

Despite the positive outlook, the insomnia treatment market, including BELSOMRA, faces several challenges.

Patent Exclusivity and Generic Competition

The loss of patent exclusivity for BELSOMRA in the US in 2029 and in Japan in 2031 will allow cheaper generic versions to enter the market, potentially eroding sales for the branded product. Similarly, Dayvigo is set to lose market exclusivity in the US in 2031, which could impact the overall market dynamics[1].

Pricing and Regulatory Barriers

Drug pricing and market exclusivity are significant obstacles. The high cost of innovative treatments like DORAs can limit their adoption, especially in markets with strict price controls. Additionally, regulatory hurdles can slow the penetration of new therapies, affecting their market growth[1].

Competitive Landscape

BELSOMRA operates in a competitive landscape that includes other DORAs and traditional insomnia treatments.

Other DORAs

Eisai’s Dayvigo (lemborexant) and Idorsia’s Quviviq (daridorexant) are key competitors in the DORA segment. These drugs, like BELSOMRA, offer a new mechanism of action and are gaining traction in the market[1].

Traditional Treatments

Traditional hypnotics such as Z-drugs, benzodiazepines, and low-dose sedating antidepressants still hold a significant market share. However, DORAs are increasingly capturing patient share from these older pharmacological treatments[1].

Pipeline and Future Prospects

The future growth of the insomnia treatment market, including BELSOMRA, will be influenced by pipeline products.

Late-Stage Pipeline Products

Products like Vanda Pharmaceuticals’ Hetlioz (tasimelteon), EUSOL’s SM-1 (diphenhydramine + lorazepam + zolpidem), Taisho Pharmaceutical’s vornorexant, and Imbrium Therapeutics’s sunobinop are expected to contribute $330.2 million in sales by 2032. These launches will further diversify the treatment options available and potentially drive market growth[1].

Regional Market Dynamics

The US is the largest market for insomnia treatments, accounting for 81.9% of sales in the seven major markets by 2032. The dominance of the US market is due to its larger insomnia population and higher drug prices. New launches, including Hetlioz, SM-1, and sunobinop, are forecast to occur primarily in the US market[1].

Key Takeaways

  • Market Growth: The insomnia treatment market is expected to grow at a CAGR of 2.6% from 2022 to 2032, driven by DORAs like BELSOMRA.
  • Competitive Landscape: BELSOMRA competes with other DORAs and traditional insomnia treatments, but its unique mechanism of action sets it apart.
  • Financial Impact: BELSOMRA contributes to Merck's pharmaceutical sales, though specific figures are not detailed.
  • Challenges: Loss of patent exclusivity, generic competition, and pricing barriers are significant challenges.
  • Future Prospects: Pipeline products and increased uptake of DORAs will drive future market growth.

FAQs

What is the mechanism of action of BELSOMRA?

BELSOMRA works by selectively blocking orexin receptors, which suppresses the wake drive in the brain, helping patients fall asleep and stay asleep[3].

How is the market for insomnia treatments expected to grow?

The market is anticipated to grow at a CAGR of 2.6% from $3.2 billion in 2022 to $4.1 billion in 2032, driven by the increasing use of DORAs[1].

What are the main challenges facing BELSOMRA in the market?

The main challenges include the loss of patent exclusivity, generic competition, and pricing barriers[1].

Which regions are expected to drive the growth of the insomnia treatment market?

The US is expected to be the largest market, accounting for 81.9% of sales in the seven major markets by 2032[1].

What pipeline products are expected to contribute to the market growth?

Products like Hetlioz, SM-1, vornorexant, and sunobinop are expected to contribute $330.2 million in sales by 2032[1].

Sources

  1. European Pharmaceutical Review: Market outlook to 2032: future trends across the seven major markets.
  2. Business Wire: Merck Announces Third-Quarter 2024 Financial Results.
  3. Merck: Merck's Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States.
  4. Practical Neurology: Belsomra: A First Look.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.